We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+31.06%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$4.93B
AUM Growth
+$243M
Cap. Flow
-$263M
Cap. Flow %
-5.34%
Top 10 Hldgs %
50.68%
Holding
90
New
9
Increased
18
Reduced
10
Closed
20

Top Buys

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$113M
2
ACRV icon
Acrivon Therapeutics
ACRV
+$61.1M
3
VOR icon
Vor Biopharma
VOR
+$57.5M
4
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$53.5M
5
PCVX icon
Vaxcyte
PCVX
+$50.1M

Top Sells

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$180M
2
BIIB icon
Biogen
BIIB
+$114M
3
RLMD icon
Relmada Therapeutics
RLMD
+$74M
4
ASND icon
Ascendis Pharma A/S
ASND
+$70.9M
5
THRD
Third Harmonic Bio
THRD
+$49.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
2 Financials 0.51%
3 Miscellaneous 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMVP icon
76
PMV Pharmaceuticals
PMVP
$72.7M
– –
-1,710,265
Closed -$20.4M
PYXS icon
77
Pyxis Oncology
PYXS
$278M
– –
-764,653
Closed -$1.51M
RLAY icon
78
Relay Therapeutics
RLAY
$4.16B
– –
-717,618
Closed -$16.1M
RLMD icon
79
Relmada Therapeutics
RLMD
$474M
– –
-2,000,000
Closed -$74M
FTH
80
Faeth Therapeutics
FTH
$914M
– –
-34,176
Closed -$1.06M
SYBX
81
DELISTED
Synlogic
SYBX
– –
-307,894
Closed -$4.39M
SYRE icon
82
Spyre Therapeutics
SYRE
$8.02B
– –
-418
Closed -$5K
TIL icon
83
Instil Bio
TIL
$48.9M
– –
-383,540
Closed -$37.1M
VERA icon
84
Vera Therapeutics
VERA
$2.43B
– –
-1,578,820
Closed -$33.6M
PRDS
85
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
– –
-6,175,038
Closed -$11.4M
APTX
86
DELISTED
Aptinyx Inc. Common Stock
APTX
– –
-1,954,698
Closed -$720K
FLACU
87
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
– –
-1,000,000
Closed -$9.98M
BLSA
88
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
– –
-1,250,000
Closed -$12.5M
FVAM
89
DELISTED
5:01 Acquisition Corp
FVAM
– –
-750,000
Closed -$7.5M
FMTX
90
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
– –
-9,011,651
Closed -$180M
1 2 3
4

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, RA Capital Management held 90 positions worth $4.93B, up 5.2% from $4.69B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

RA Capital Management withdrew a net $263M in Q4 2022, closing 20 positions and reducing 10 holdings. Its most notable exit was Forma Therapeutics Holdings, Inc. Common Stock, an estimated $180M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials and Miscellaneous.

Against the trend, RA Capital Management opened a new position in Inhibrx, Inc. Common Stock worth $95M.

  • RA Capital Management's largest Q4 2022 buy was Inhibrx, Inc. Common Stock: 3,853,867 shares worth $95M.
  • RA Capital Management added most to Vor Biopharma in Q4 2022, an estimated $57.5M increase.
  • RA Capital Management's biggest Q4 2022 reduction was Biogen, cutting an estimated $114M.
  • RA Capital Management fully exited Forma Therapeutics Holdings, Inc. Common Stock in Q4 2022, selling an estimated $180M.
  • RA Capital Management's ten largest holdings make up 51% of its $4.93B portfolio in Q4 2022.
  • RA Capital Management opened 9 new positions and closed 20 in Q4 2022.
  • RA Capital Management's portfolio value rose 5.2% quarter-over-quarter to $4.93B.

Based on RA Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.